重大新闻！杭州村民众筹1.2亿造大别墅！每户85万喜提新家，背后创新模式获点赞

杭州村民众筹1.2亿造大别墅！每户85万喜提新家，背后创新模式获点赞

浙江杭州 - 2024年1月12日，浙江省杭州市临平区博陆村26户村民欢喜入住由他们共同众筹建设的三层大别墅。这标志着临平区首个农村危旧房集中改造项目取得圆满成功。

该项目总投资1.2亿元，由178户村民共同出资建设。每户别墅面积约300平方米，配备露台、落地窗、大院子等，设施齐全，环境优美。村民们对新房十分满意，纷纷表示，这不仅改善了他们的居住条件，也圆了他们多年的别墅梦。

创新模式破解农村危旧房改造难题

博陆村位于杭州市临平区，地处偏远，交通不便。村内大部分房屋建于上世纪80年代，至今已有近40年历史，存在房屋老旧、结构不佳、安全隐患等问题。随着近年来城镇化发展，部分村民外出务工，村内常住人口减少，传统的“一户一宅”自建模式难以满足村民居住需求。

为了有效解决农村危旧房改造难题，博陆村在区委、街道的大力支持下，创新提出“村民众筹、集中建设”模式。该模式打破了传统农村自建房的局限，通过村民集资、统一规划、集中建设的方式，有效降低了建设成本，提高了建设质量，缩短了建设周期，并实现了配套设施共享，美化了村容村貌。

村民点赞：众筹建房省钱又省心

村民朱先生是此次分房的村民之一。他告诉记者，他家老房建于1994年，面积只有100多平方米，随着家庭人口增加，居住空间越来越拥挤。而且老房年久失修，存在很多安全隐患。一直以来，他想翻建房屋，但苦于资金不足，迟迟未能动工。

“听说村里启动了危旧房集中改造项目，可以大家集资建新房，我第一时间就报了名。”朱先生说。他算了一笔账，按照每户300平方米的面积计算，自己家如果单独建房，加上装修等费用，至少需要150万元以上。而现在众筹建房，每户只需要85万元，省了一半的钱。

“而且众筹建房省心多了。”朱先生说。以前农村自建房，需要自己操办所有事项，从选材、施工到监工，样样都要亲力亲为，十分辛苦。现在村里统一招标、统一施工、统一验收，村民们只需要定期去工地看看进度就可以了。

项目示范效应显现 未来将推广复制

博陆村村民众筹建房的创新模式，得到了各级领导和村民的一致好评。临平区委、区政府将该项目列为重点工程，并给予资金和政策支持。

临平区住建局相关负责人表示，博陆村村民众筹建房项目，是解决农村危旧房改造难题的一次有益尝试，具有较强的示范效应。下一步，将把该项目作为典型经验，在全区范围内推广复制，帮助更多村民改善居住条件。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.